New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
07:32 EDTCBST, SHPGCubist volatility expected to move on Shire rumored to weigh bid report
Cubist (CBST) option volatility is expected to move on Shire (SHPG) rumored to weigh a bid, FT Alphaville says. Overall option implied volatility of 41 is above its 26-week average of 38 according to Track Data, suggesting large price movement.
News For CBST;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
08:21 EDTSHPGShire the 'real winner' after NPS gets approval for Natpara, says Janney Capital
Janney Capital said NPS Pharmaceuticals' (NPSP) getting FDA approval for its second marketed product, Natpara, is a positive for NPS, but that the "real winner" is Shire (SHPG), noting that the company had no stipulations dependent on Natpara approval in its deal to buy NPS. The firm expects the acquisition to move forward as planned and maintains its Neutral rating on NPS shares.
07:27 EDTSHPGShire price target raised to $263 from $247 at Jefferies
Subscribe for More Information
05:26 EDTSHPGShire SHP609 receives FDA fast track designation
Subscribe for More Information
January 25, 2015
12:30 EDTSHPGShire comments on press release from NPS Pharma on Natpara approval
Subscribe for More Information
January 22, 2015
07:38 EDTCBSTARIAD appoints DesRosier as Chief Legal and Administrative Officer
Subscribe for More Information
05:27 EDTSHPGShire reports positive response from European DCP for Elvanse Adult
Subscribe for More Information
January 21, 2015
08:02 EDTCBSTMerck completes tender offer to acquire Cubist
Merck (MRK) announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals (CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667 shares of common stock of Cubist were validly tendered and not properly withdrawn from the tender offer, representing approximately 75.7% of the outstanding common stock of Cubist on a fully diluted basis. All of such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for all such shares. Following consummation of the tender offer, Merck expects to complete the acquisition of Cubist later today through a merger of Merckís wholly owned subsidiary with and into Cubist without stockholder approval. Upon completion of the merger, all outstanding shares of common stock of Cubist, other than shares held by Cubist in treasury or shares held by Cubistís stockholders who are entitled to and properly exercise appraisal rights under Delaware law, will be canceled and converted into the right to receive cash equal to the $102.00 offer price per share without interest, less any applicable withholding taxes. In addition, upon completion of the merger, Cubist will become a wholly owned subsidiary of Merck and the common stock of Cubist will cease to be traded on the NASDAQ Stock Market.
January 20, 2015
17:18 EDTCBSTDana Holding to replace Cubist in S&P 400 as of 1/22 close
Subscribe for More Information
14:06 EDTSHPGCitizens, Keysight identified as long positions by Einhorn
Subscribe for More Information
10:20 EDTCBSTOptions with decreasing implied volatility
Options with decreasing implied volatility: RPRX TLM BBY GME CBST NPSP
08:10 EDTSHPGShire price target raised to $247 from $228 at Jefferies
Subscribe for More Information
January 16, 2015
16:36 EDTSHPGMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information
10:15 EDTCBSTOptions with decreasing implied volatility: BBY ETE CBST
Subscribe for More Information
January 13, 2015
17:37 EDTSHPGShire targets $10B in organic product sales by 2020
Subscribe for More Information
08:04 EDTCBSTCubist announces withdrawal of CVRs from Nasdaq Global Select Market
Cubist Pharmaceuticals announced that it will voluntarily withdraw the contingent value rights, or CVRs, it issued under a Contingent Value Rights Agreement dated October 24, 2013 from listing on the NASDAQ Global Select Market on February 2, 2015, contemporaneously with their redemption. The CVRs are currently listed under the symbol CBSTZ. Cubist is withdrawing the CVRs from listing in connection with the Failure Purchase of all outstanding CVRs on February 2, 2015 in accordance with the terms of the CVR Agreement. On February 2, 2015, all outstanding CVRs will be purchased by Cubist and cancelled. Cubist has not arranged, nor does it intend to arrange, for the listing of the CVRs on another securities exchange or for quotation on any other quotation medium. Cubist currently anticipates that it will file a Form 25 with the U.S. SEC on January 23, 2015 to commence the delisting process. It is expected that the delisting will take effect on February 2, 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use